Log in to your Inderes Free account to see all free content on this page.
Glycorex Transplantation
1.795
SEK
-4.52 %
GTAB B
NGM Main Regulated
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
-4.52%
+24.65%
+23.79%
+90.55%
+35.47%
+15.81%
-80.78%
-81.46%
-82.32%
glycorex.com
Glycorex Transplantation is a biotechnology company. The company conducts research, development, and marketing within the field of organ transplantation. The main product of the company, Glycosorb-ABO, enables transplants irrespective of the blood type of the donors and the recipients. Transplants with the help of the company's product have been carried out worldwide. Glycorex Transplantation was founded in 1996 and is based in Lund.
Revenue
29.96M
EBIT %
-101.07 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NGM Main Regulated
GTAB B
Daily low / high price
1.72 / 1.875
SEK
Market cap
132.57M SEK
Turnover
76.33K SEK
Volume
43K
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 10.9 % | 7.8 % |
| Wendt Investment AB | 7.1 % | 5.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO
Glycorex Transplantation: Glycosorb® ABO is pushing the boundaries in paediatric blood group incompatible heart transplantation
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio